BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 18835037)

  • 1. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells.
    d'Argouges S; Wissing S; Brandl C; Prang N; Lutterbuese R; Kozhich A; Suzich J; Locher M; Kiener P; Kufer P; Hofmeister R; Baeuerle PA; Bargou RC
    Leuk Res; 2009 Mar; 33(3):465-73. PubMed ID: 18835037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
    Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
    Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.
    Brandl C; Haas C; d'Argouges S; Fisch T; Kufer P; Brischwein K; Prang N; Bargou R; Suzich J; Baeuerle PA; Hofmeister R
    Cancer Immunol Immunother; 2007 Oct; 56(10):1551-63. PubMed ID: 17310380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
    Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
    Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
    Csóka M; Strauss G; Debatin KM; Moldenhauer G
    Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.
    Dreier T; Lorenczewski G; Brandl C; Hoffmann P; Syring U; Hanakam F; Kufer P; Riethmuller G; Bargou R; Baeuerle PA
    Int J Cancer; 2002 Aug; 100(6):690-7. PubMed ID: 12209608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy.
    Zimmerman Z; Maniar T; Nagorsen D
    Int Immunol; 2015 Jan; 27(1):31-7. PubMed ID: 25239133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
    Fan D; Li W; Yang Y; Zhang X; Zhang Q; Yan Y; Yang M; Wang J; Xiong D
    J Hematol Oncol; 2015 Oct; 8():108. PubMed ID: 26444983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
    Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
    J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.
    Nagorsen D; Bargou R; Ruttinger D; Kufer P; Baeuerle PA; Zugmaier G
    Leuk Lymphoma; 2009 Jun; 50(6):886-91. PubMed ID: 19455460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
    Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
    J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16.
    Pörtner LM; Schönberg K; Hejazi M; Brünnert D; Neumann F; Galonska L; Reusch U; Little M; Haas R; Uhrberg M
    Cancer Immunol Immunother; 2012 Oct; 61(10):1869-75. PubMed ID: 22976535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
    Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
    Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
    Boehrer S; Schroeder P; Mueller T; Atz J; Chow KU
    Anticancer Drugs; 2011 Jul; 22(6):519-30. PubMed ID: 21637160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
    Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
    Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Production, identification and redirected cytotoxicity of CD3/CD19 bispecific monoclonal antibody].
    Chen X; Shen D; Sun T; Bai J; Huang L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Oct; 20(5):351-6. PubMed ID: 11717991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent.
    Gruen M; Bommert K; Bargou RC
    Cancer Immunol Immunother; 2004 Jul; 53(7):625-32. PubMed ID: 15175907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells.
    Hönemann D; Kufer P; Rimpler MM; Chatterjee M; Friedl S; Riecher F; Bommert K; Dörken B; Bargou RC
    Leukemia; 2004 Mar; 18(3):636-44. PubMed ID: 14737072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.